{"id":"https://openalex.org/W3111069302","doi":"https://doi.org/10.1007/s11523-020-00778-y","title":"Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA","display_name":"Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA","publication_year":2020,"publication_date":"2020-12-07","ids":{"openalex":"https://openalex.org/W3111069302","doi":"https://doi.org/10.1007/s11523-020-00778-y","mag":"3111069302","pmid":"https://pubmed.ncbi.nlm.nih.gov/33284424"},"language":"en","primary_location":{"id":"doi:10.1007/s11523-020-00778-y","doi":"https://doi.org/10.1007/s11523-020-00778-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-020-00778-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-020-00778-y.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s11523-020-00778-y.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017834828","display_name":"Fran\u00e7ois Lalibert\u00e9","orcid":"https://orcid.org/0000-0003-2601-6214","observed_orcids":["https://orcid.org/0000-0003-2601-6214"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fran\u00e7ois Lalibert\u00e9","raw_affiliation_strings":["Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004154463","display_name":"Monika Kumar Raut","orcid":"https://orcid.org/0009-0000-9538-2934","observed_orcids":["https://orcid.org/0009-0000-9538-2934"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monika Raut","raw_affiliation_strings":["Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081663611","display_name":"Xiaoqin Yang","orcid":"https://orcid.org/0000-0003-1806-1592","observed_orcids":["https://orcid.org/0000-0003-1806-1592"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoqin Yang","raw_affiliation_strings":["Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061998147","display_name":"Guillaume Germain","orcid":"https://orcid.org/0000-0002-4525-7673","observed_orcids":["https://orcid.org/0000-0002-4525-7673"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Guillaume Germain","raw_affiliation_strings":["Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada. guillaume.germain@analysisgroup.com","Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada. guillaume.germain@analysisgroup.com","institution_ids":[]},{"raw_affiliation_string":"Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108809055","display_name":"Akash Nahar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Akash Nahar","raw_affiliation_strings":["Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075781740","display_name":"Kaushal D. Desai","orcid":"https://orcid.org/0000-0002-8941-2858","observed_orcids":["https://orcid.org/0000-0002-8941-2858"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kaushal D. Desai","raw_affiliation_strings":["Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039497950","display_name":"Sean D. MacKnight","orcid":"https://orcid.org/0000-0001-5032-2110","observed_orcids":["https://orcid.org/0000-0001-5032-2110"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sean D. MacKnight","raw_affiliation_strings":["Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Groupe d'analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103684369","display_name":"Shuvayu Sankar Sen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shuvayu S. Sen","raw_affiliation_strings":["Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063896009","display_name":"Mei Sheng Duh","orcid":"https://orcid.org/0000-0001-5035-6687","observed_orcids":["https://orcid.org/0000-0001-5035-6687","https://orcid.org/0000-0002-4851-0144"]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mei Sheng Duh","raw_affiliation_strings":["Analysis Group, Inc., Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Boston, MA, USA","institution_ids":["https://openalex.org/I79463011"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5061998147"],"corresponding_institution_ids":[],"apc_list":{"value":3860,"currency":"USD","value_usd":3860},"apc_paid":{"value":3860,"currency":"USD","value_usd":3860},"fwci":0.2802,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.57472572,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":95},"biblio":{"volume":"16","issue":"1","first_page":"85","last_page":"94"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.8461999893188477,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.8461999893188477,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.06459999829530716,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.059700001031160355,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/classical-hodgkin-lymphoma","display_name":"classical Hodgkin lymphoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/relapsed-refractory-hodgkin-lymphoma","display_name":"relapsed/refractory Hodgkin lymphoma","score":0.9259999990463257},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/anti-pd-1-monoclonal-antibody","display_name":"anti-PD-1 monoclonal antibody","score":0.8650000095367432},{"id":"https://openalex.org/keywords/healthcare-resource-utilization","display_name":"healthcare resource utilization","score":0.9879999756813049},{"id":"https://openalex.org/keywords/hospitalization-rates","display_name":"hospitalization rates","score":0.7039999961853027},{"id":"https://openalex.org/keywords/outpatient-visits","display_name":"outpatient visits","score":0.9909999966621399},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.4359999895095825},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.4790000021457672},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6209999918937683},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.5690000057220459},{"id":"https://openalex.org/keywords/health-insurance-claims-data","display_name":"health insurance claims data","score":0.5979999899864197},{"id":"https://openalex.org/keywords/inverse-probability-of-treatment-weighting","display_name":"inverse probability of treatment weighting","score":0.7639999985694885},{"id":"https://openalex.org/keywords/charlson-comorbidity-index","display_name":"Charlson Comorbidity Index","score":0.6679999828338623}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9309098720550537},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.83938068151474},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8140308856964111},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6136804819107056},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5643367171287537},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4775286912918091},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4381871521472931},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37857192754745483},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3135254979133606},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.10550734400749207},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.09405902028083801}],"mesh":[{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019984","descriptor_name":"Quality Indicators, Health Care","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D019984","descriptor_name":"Quality Indicators, Health Care","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D019984","descriptor_name":"Quality Indicators, Health Care","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s11523-020-00778-y","doi":"https://doi.org/10.1007/s11523-020-00778-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-020-00778-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-020-00778-y.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},{"id":"pmid:33284424","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33284424","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7810643","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7810643","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Target Oncol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s11523-020-00778-y","doi":"https://doi.org/10.1007/s11523-020-00778-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-020-00778-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-020-00778-y.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320332932","display_name":"Merck Sharp and Dohme","ror":"https://ror.org/004nn4n27"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3111069302.pdf","grobid_xml":"https://content.openalex.org/works/W3111069302.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W165173872","https://openalex.org/W1963674127","https://openalex.org/W2029065958","https://openalex.org/W2032376637","https://openalex.org/W2036193982","https://openalex.org/W2057780602","https://openalex.org/W2061326496","https://openalex.org/W2084446054","https://openalex.org/W2118169390","https://openalex.org/W2125616358","https://openalex.org/W2159011576","https://openalex.org/W2165200673","https://openalex.org/W2339562453","https://openalex.org/W2500482667","https://openalex.org/W2504623699","https://openalex.org/W2609973112","https://openalex.org/W2761277905","https://openalex.org/W2774391334","https://openalex.org/W2794872274","https://openalex.org/W2797608577","https://openalex.org/W2804430290","https://openalex.org/W2890218354","https://openalex.org/W2895350717","https://openalex.org/W2897427708","https://openalex.org/W2903926225","https://openalex.org/W2911188335","https://openalex.org/W2976680230","https://openalex.org/W4236368282","https://openalex.org/W4256122457"],"related_works":["https://openalex.org/W3094946786","https://openalex.org/W2532961791","https://openalex.org/W2799716227","https://openalex.org/W3032782140","https://openalex.org/W2272044596","https://openalex.org/W3017309209","https://openalex.org/W2900971926","https://openalex.org/W2329670317","https://openalex.org/W4200529536","https://openalex.org/W2947266573"],"abstract_inverted_index":{"BACKGROUND:":[0],"Patients":[1],"with":[2,83,121],"classical":[3],"Hodgkin":[4],"lymphoma":[5],"(cHL)":[6],"relapsed":[7],"or":[8,15,126],"refractory":[9],"(R/R)":[10],"disease":[11],"who":[12],"relapse":[13],"after":[14,235],"are":[16],"ineligible":[17],"for":[18,54,139],"autologous":[19],"stem":[20],"cell":[21],"transplantation":[22],"have":[23],"a":[24],"poor":[25],"prognosis.":[26],"Recently,":[27],"the":[28,38,60,76,92,156,193,198,210,217,223,238,248,253,279,296],"anti-PD1":[29],"monoclonal":[30],"antibodies":[31],"nivolumab":[32,90,127,224,241,280,299],"and":[33,41,47,147,150,160,181,187,240,244,268,285,298,318],"pembrolizumab":[34,87,125,186,218,239,254,297,311],"were":[35,109,153,168,190,289],"approved":[36],"by":[37],"US":[39],"Food":[40],"Drug":[42],"Administration":[43],"(FDA;":[44],"May":[45],"2016":[46],"March":[48],"2017,":[49],"respectively)":[50],"as":[51],"treatment":[52,133],"options":[53],"R/R":[55],"cHL":[56,84,122,307],"patients.":[57],"OBJECTIVE:":[58],"In":[59,302],"absence":[61],"of":[62,81,132,166,179,212,260,283,316],"comparative":[63],"clinical":[64],"trials":[65],"between":[66,144,170,293],"these":[67],"agents,":[68],"this":[69,112,303],"observational":[70],"study":[71,116,194],"was":[72,135,201,214,232],"conducted":[73],"to":[74,89,137,222,322],"evaluate":[75],"healthcare":[77],"resource":[78],"utilization":[79],"(HRU)":[80],"patients":[82,120,183,251,294,308,323],"initiated":[85,123,184,309,324],"on":[86,124,185,310,325],"compared":[88,169,221,321],"in":[91,111,141,192,206,216,237,252,278,295],"USA.":[93],"PATIENTS":[94],"AND":[95],"METHOD:":[96],"Healthcare":[97],"insurance":[98],"claims":[99],"from":[100],"Symphony":[101],"Health's":[102],"IDV\u00ae":[103],"(Integrated":[104],"Dataverse)":[105],"(July":[106],"2014-June":[107],"2018)":[108],"used":[110,136],"retrospective":[113],"study.":[114],"The":[115],"population":[117],"included":[118,191],"adult":[119,306],"(index":[128],"date).":[129],"Inverse":[130],"probability":[131],"weighting":[134,236],"adjust":[138],"differences":[140],"patient":[142],"characteristics":[143],"cohorts.":[145,300],"All-cause":[146],"cHL-related":[148,269,286,319],"hospitalizations":[149,262,270,320],"outpatient":[151,287],"visits":[152,288],"measured":[154],"during":[155],"observation":[157,249],"(post-index)":[158],"period":[159],"reported":[161],"per":[162],"patient-year":[163],"(PPY).":[164],"Rates":[165,282],"HRU":[167],"cohorts":[171,242],"using":[172],"rate":[173],"ratios":[174],"(RRs).":[175],"RESULTS:":[176],"A":[177],"total":[178],"92":[180],"218":[182],"nivolumab,":[188],"respectively,":[189],"population.":[195],"After":[196],"weighting,":[197],"mean":[199],"age":[200],"similar":[202],"at":[203],"55":[204],"years":[205],"both":[207],"cohorts,":[208],"while":[209],"proportion":[211],"females":[213],"lower":[215,258,314],"cohort":[219,225,255],"(35.3%)":[220],"(44.1%).":[226],"Mean":[227],"Quan-Charlson":[228],"Comorbidity":[229],"Index":[230],"score":[231],"well":[233],"balanced":[234],"(4.2":[243],"4.3,":[245],"respectively).":[246],"During":[247],"period,":[250],"had":[256,312],"significantly":[257,313],"rates":[259,315],"all-cause":[261,284,317],"(RR":[263,271],"[95%":[264,272],"CI]":[265,273],"0.33":[266],"[0.09-0.80])":[267],"0.14":[274],"[0.02-0.37])":[275],"than":[276],"those":[277],"cohort.":[281],"not":[290],"statistically":[291],"different":[292],"CONCLUSIONS:":[301],"real-world":[304],"study,":[305],"nivolumab.":[326]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}